Exchange: NASDAQ·Updated 07:59 PM EDT

RXRX News

News
all
press releases
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.63, representing a -3.14% change from its previous close.
Zacks
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.63, representing a -3.14% change from its previous close.
Zacks
More News
Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.
Stocktwits
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.7, indicating a -1.2% shift from the previous trading day.
Zacks
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.
Zacks
Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.05, representing a +2.02% change from its previous close.
Zacks
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursions RNA Foundation Model
Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursions RNA Foundation Model. Tempus and Recursion have...
Business Wire
FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug
AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.
Zacks
Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
Recursion Pharmaceuticals (NASDAQ:RXRX) reported second-quarter financial results on Wednesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered byread more...
Benzinga
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.
Zacks
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.16, signifying a -1.71% move from its prior day's close.
Zacks

Advertisement|Remove ads.